BAY 81-8973, a full-length recombinant factor VIII for the treatment of hemophilia A: product review

Podobne zapisy

• Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A
  od: Pocoski, Jennifer, i wsp.
  Wydane: (2016)
• BAY 81‐8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ≤2 years
  od: Mahlangu, Johnny, i wsp.
  Wydane: (2020)
• Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II)
  od: Kavakli, K, i wsp.
  Wydane: (2015)
• Increased branching and sialylation of N-linked glycans correlate with an improved pharmacokinetic profile for BAY 81–8973 compared with other full-length rFVIII products
  od: Teare, John M, i wsp.
  Wydane: (2019)
• Efficacy and safety of prophylaxis with BAY 81‐8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial
  od: Yang, Renchi, i wsp.
  Wydane: (2019)